Source: International Congress 2016 – New and old therapies for chronic lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Steven Nathan (Falls Church, United States of America), Steven Nathan, Carlo Albera, Ulrich Costabel, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Carlos Pereira, Jeffrey Swigris, Andrey Pavlov, John Stauffer, Bann-Mo Day, Willis Chou, Athol Wells. Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies. Eur Respir J 2016; 48: Suppl. 60, 1765

Member's Comments

No comment yet.

Related content which might interest you: Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Correlation of composite physiologic index with 6-minute walk test variables in patients with idiopathic interstitial pneumonias Source: International Congress 2016 – Clinical exercise physiology in health and disease Year: 2016 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 25: 96-103 Year: 2005 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016